Treatment of Atypical Ductal Hyperplasia

Immediate Surgical Management

• The National Comprehensive Cancer Network (NCCN) recommends excisional biopsy after core needle biopsy diagnoses atypical ductal hyperplasia (ADH) due to the risk of cancer underestimation, with upgrade rates ranging from 15-42% to ductal carcinoma in situ (DCIS) or invasive cancer 1, 2, 3
• Larger tissue samples are needed to definitively rule out concurrent malignancy that may have been missed on the limited core needle biopsy specimen 1, 2

Risk Reduction Therapy After Excision

• The National Surgical Adjuvant Breast and Bowel Project (NSABP) guidelines state that tamoxifen provides a 75% reduction in the occurrence of invasive breast cancer in women with ADH and should be strongly considered for risk reduction, representing Category 1 evidence (highest level) 4
• Tamoxifen treatment duration is 5 years at a dose of 20 mg daily 4
• Women with ADH face a 4- to 5-fold increased risk of developing invasive breast cancer, with continuous annual risk of approximately 0.5-1.0% 4

Long-Term Surveillance Protocol

• All women with ADH require lifelong surveillance regardless of whether they undergo surgery or take tamoxifen, including history and physical examination every 6-12 months for 5 years, then annually, and annual diagnostic mammography 4
• Consider more intensive screening in patients with ADH and a family history of breast cancer in a first-degree relative 5

Surgical Excision and Guideline Recommendations for Atypical Ductal Hyperplasia (ADH)

NCCN Guideline Recommendations

• The National Comprehensive Cancer Network (NCCN) mandates surgical excision for all patients diagnosed with ADH on core‑needle biopsy because of a substantial risk of cancer underestimation. 6

Rationale for Excision

• Core‑needle biopsy provides a limited tissue sample that may miss concurrent malignancy elsewhere in the lesion, supporting the need for definitive surgical excision. 7

Position on Active Surveillance

• The NCCN states that active surveillance for ADH remains investigational and is not endorsed; surgical excision continues to be the standard of care. [6][8]

Risk of Invasive Breast Cancer in Women with Atypical Ductal Hyperplasia

Baseline Risk After Diagnosis

• Women diagnosed with atypical ductal hyperplasia have a 4‑ to 5‑fold higher risk of developing invasive breast cancer, corresponding to an annual incidence of approximately 0.5–1.0 % per year. 9

Influence of Family History

• The risk of invasive breast cancer is approximately doubled in women with atypical ductal hyperplasia who also have a first‑degree family history of breast cancer. 9